Ambrose Healthcare Ltd (Ambrose Healthcare), announces today the expansion of its collaborative network, with the inclusion of two rare disease specialists:
UK’s CamRARE (Cambridge Rare Disease Network); and
UK Digital Health
The U.S. NIH recognises some 7,000 rare diseases[1], affecting around 400 million people globally[2], for which approximately 600 therapies have been approved to date by the U.S. Food and Drug Administration[3]. As such there is still much to be done to close this gap.
CamRARE is a platform for change with an infrastructure that unites patients, advocates, experts and leaders to address the challenges faced by people affected by rare diseases. By sharing knowledge and experience, and working together, the journey towards better diagnosis, treatment and support for patients and their families is smoother and more certain.
Jo Balfour, founding member and Managing Director of CamRARE, is the master behind the organisation’s innovative, patient-centric networking forums and educational events: RAREfest and RAREsummit. In addition, she is founder of CamRARE’s Unique Feet, a regional community support group for families affected by rare conditions and gives strategic guidance and direction to the board and oversees the charity’s operations. CamRARE works with 200 rare disease patient groups.
Victoria Wilbraham-Mitchell, Founder and Principal of Wales based UK Digital Health is a senior healthcare executive with over 25 years of experience of product launches and commercialisation within the Digital, MedTech, Devices and Pharmaceutical industries. She has seen the UK, European and wider global healthcare markets grow and change over time, leading to one of the most exciting evolutions – a global landscape that embraces innovation in patient care.
Ambrose Healthcare’s collaborations with the UK’s CamRARE and UK Digital Health will support clarification of the unmet patient needs, clinical development of Ambrose Healthcare’s drug products and delivery of new treatments for rare diseases and unmet clinical needs of patients managed in hospital and specialist care environments.
Commenting, Jo Balfour, Managing Director of CamRARE said, ”CamRARE, working to support 200 rare disease patient groups, is at the leading edge of understanding the unmet needs and quality of life challenges for these patients. We are impressed by the knowledge and experience of the Ambrose Healthcare team in the development of new treatments for rare disease patients and delighted to be collaborating with and supporting the Company to that end.”
Commenting, Victoria Wilbraham-Mitchell, Founder and Principal of Wales based UK Digital Health said, “The UK, EU and and wider global markets can seem complex to enter. By simplifying and guiding through some of that complexity, and supporting commercial evaluation & planning, I look forward to working with the Ambrose Healthcare team to successfully launch and provide patients access to much needed new and improved treatment options.”
Toby Wilson Waterworth, Founder and Chair of Ambrose Healthcare Ltd, commented: “I am delighted to have two such experienced and well-respected specialists on board to help Ambrose Healthcare fulfil its potential in such an important field.”
About CamRARE (Cambridge Rare Disease Network)
One in 17 people will develop a rare condition at some point in their lives – that’s 3.5 million in the UK alone and over 350 million worldwide. If we were to take into account their close families, we could estimate that one in five of us will be impacted by a rare condition. Individually the unmet needs of those living with a rare condition are often seen in isolation. CamRARE brings their voices together to create a powerful chorus.
About UK Digital Health
UK Digital Health are passionate about helping UK and Global businesses launch their digital tech, med tech and life science innovations successfully into the UK and global markets. We work in partnership with companies, bringing our industry experience and knowledge of the UK NHS, the private sector and global healthcare systems to help clients identify the right opportunities, whilst strategically navigating the challenges of launch into the UK market and beyond.
As industry experts, we provide bespoke services to UK and Global clients who are looking to make a positive impact on healthcare. We partner with clients to simplify the complexity of national and international healthcare markets, helping to align priorities and successfully partner with the NHS, private providers, and healthcare systems globally.
About Ambrose Healthcare (www.ambrosehc.com)
Ambrose Healthcare Ltd is a specialist pharmaceutical company, with ambitious plans to address ‘market pull’ – the call from patient groups and the medical community – to provide treatments for rare diseases and the unmet medical needs of patients managed in a hospital or specialist care setting.
Whilst the NIH lists more than 7,000 rare diseases[1], FDA reports only 600 drug approvals to date in 2020[3]. Some 400 million people worldwide are affected by rare diseases[2].The Ambrose Healthcare team is seeking to replicate the success of its previous venture, where, applying the same rare disease, hospital focused strategy, and receiving $50M of investment in equity and grants, it delivered a product portfolio valued at $500M (Top 4 Global Accountancy Firm).
Ambrose Healthcare, through acquisition, licencing and collaboration, is developing a portfolio of commercial and clinical stage therapeutic assets.
The company will commercialise its products in its core markets of the US, Europe, and the Middle East, and in other territories via licencing or distribution agreements with established pharmaceutical companies.
References:
1. U.S. National Institutes of Health (rarediseases.info.nih.gov/about)
2. CamRARE – Cambridge Rare Disease Network (www.camraredisease.org/)
3. National Organization for Rare Disorders (rarediseases.org/new-study-investigates-the-number-of-available-orphan-products-generics-and-biosimilars/)
Forward looking statements
While Ambrose Healthcare believes any forward-looking statements in this press release are accurate, the statements represent Ambrose Healthcare’s beliefs only as of the date of this press release. A number of factors could cause actual events or results to differ materially from those indicated by such statements. These forward-looking statements involve risks and uncertainties. In addition, risks and results in clinical trials may not be indicative of risks or results from later stage or larger scale trials, and there is no assurance of regulatory approval. Existing and prospective investors should not place undue reliance on the forward-looking statements contained in a press release and instead should make their own determinations as to the reliability of such statements. Ambrose Healthcare undertakes no intent or obligation to update the information contained in this press release as new information becomes available.
For more information, please contact:
Ambrose Healthcare
Adam Michael, Director of Communications
adam.michael@ambrosehc.com +44 7775 881 813
CamRARE
Jo Balfour, Founder and Managing
Directorjo@camraredisease.org +44 7725 039780
UK Digital Health
Victoria Wilbraham-Mitchell, Founder and Principal
vwilbraham@ukdigitalhealth.com+44 333 305 4480